Plasma fibrinopeptide A (FPA), fibrinopeptide B/31-42 (Bj31-42), fibrinopeptide B/315-42 (B1315-42), tissue-type plasminogen activator (t-PA), D-dimer and serum FDP-E levels were determined in 16 patients (AML 4, AMoL 1, ALL 6, CMLblastic crisis 1, CLL 1, Malignant Lymphoma 3) with hematological malignancy without DIC. FPA levels at the time of before and during therapy were significantly higher than normal control levels. And in clinical remission state, FPA levels decreased to almost normal range. This tendency was especially remarkable in 5 patients with acute leukemia and the sequential FPA levels were related to the disease activity. BQ 1-42, Bj3 15-42, t-PA levels were significantly higher than normal control, but were not related to the disease activity. D-dimer, FDP-E levels were also significantly higher than normal control, and had a marked relationship with the grade of DIC.
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